New MenB vaccine trial aims to protect babies to adults

NCT ID NCT04825223

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tested a new meningococcal B vaccine in 576 healthy people, from infants to adults. Researchers checked for side effects and measured immune responses, comparing the new vaccine to two already-approved ones. The goal was to see if the vaccine is safe and triggers a strong immune defense.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • AMR El Dorado Site Number : 8400018

    El Dorado, Kansas, 67042, United States

  • Alliance for Multispecialty Research LLC Site Number : 8400013

    Wichita, Kansas, 67205, United States

  • Brengle Family Medicine Site Number : 8400044

    Indianapolis, Indiana, 46260, United States

  • California Research Foundation Site Number : 8400005

    San Diego, California, 92123-1881, United States

  • Investigational Site Number : 6300001

    San Juan, 00918, Puerto Rico

  • Investigational Site Number : 6300003

    Ponce, 00716, Puerto Rico

  • Lakeview Clinical Research Site Number : 8400029

    Guntersville, Alabama, 35976-2206, United States

  • PAS Research Site Number : 8400032

    Tampa, Florida, 33613, United States

  • Prime Global Research, Inc. Site Number : 8400043

    The Bronx, New York, 10456, United States

  • The Research Center of the Upstate Site Number : 8400008

    Greenville, South Carolina, 29607, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.